Kornimate/medical-research-clean huggingface dataset:
the relationship between exercise frequency, intensity, and restoration of cardiometabolic health

Conditions: Overweight or Obesity

Summary: regular physical activity is well established to decrease the risk of cardiometabolic diseases. while research has characterized responses based on exercise intensity, many beneficial effects of exercise are transient in nature, and therefore exercise frequency may play an important, yet currently under-appreciated, role in improving health. the purpose of this study is to determine the efficacy of 6-week high-frequency endurance (end) or low-frequency sprint (sit) training with respect to reducing clinically relevant cardiometabolic risk factors in overweight/obese males. it is hypothesized that end, performed at a greater frequency than sit, will markedly improve cardiometabolic health, while low-frequency sit will not.

involvement in regular physical activity is known to elicit systemic adaptations and reduce the risk of cardiometabolic diseases, including hypertension, obesity, dyslipidemia, and hyperglycemia. traditional physical activity recommendations suggest that 150 minutes of moderate-intensity continuous endurance (end) exercise dispersed over 5 days per week is sufficient to improve physical fitness in adults. however, given the commonly cited barrier of "lack of time," literature has recently focused on time effective sprint interval training (sit), obtaining equivalent increases in aerobic capacity and acute glycemic regulation compared to classical end exercise when protocols are work-matched. despite these similarities, end is conducive to daily sessions not feasible of sit. as improvements in many clinically relevant risk factors are transient in nature following exercise, it remains imperative to assess the implications of variable frequency exercise regimes performed as per general practice (i.e. high-frequency end, low-frequency sit). furthermore, improvements in cardiovascular outcomes following end have been shown, in some instances, to be absent in response to sit, suggesting end may be more beneficial for cardiovascular health. therefore, the current study aims to assess several markers of cardiovascular (aerobic capacity, blood pressure, arterial stiffness, vascular endothelial function) and metabolic (glucose tolerance, lipid tolerance, body composition) health following 6-weeks of high-frequency end or low-frequency sit, performed as per general practice. combined, this research will provide important insight into the under-appreciated role of exercise frequency for improving cardiometabolic health.

Eligibility criteria:
inclusion criteria: * male, aged 18-70 years * body mass index (bmi) \> 25 kg/m\^2 (classified as overweight or obese) * sedentary (\<100 minutes moderate physical activity per week) * approval for vigorous exercise via physical activity readiness questionnaire (parq+) exclusion criteria: * prescribed with glucose lowering medications * smoker * not cleared for physical activity

Keywords: endurance training sprint interval training glycemic regulation lipid homeostasis cardiovascular health
the effects of different exercise approaches in patients with chronic low back pain

Conditions: Chronic Low-back Pain

Summary: identification of the effects of yoga, stabilization exercise and aerobic exercise approaches on physical and cognitive variables in individuals with low back pain.

patients participating in the study were divided three parallel groups. the patients in the stabilization exercise group were instructed to perform spinal stabilization exercises, the patients in the yoga group were instructed to perform yoga program consisting of breathing, relaxation and flexibility exercises. the patients in the aerobic exercise group were instructed to perform aerobic walking training. the severity of the pain evaluated through visual analog scale, functional status and quality of life, alexithymia, kinesiophobia, catastrophic pain, back awareness, cognitive function evaluated through oswestry disability index(odi), nottingham health profile (nhp), toronto alexithymia scale, fear avoidance beliefs questionnaire, pain catastrophizing scale, fremantle back awareness scale, montreal cognitive assessment respectively. assessments were repeated before and after the treatment.

Eligibility criteria:
inclusion criteria: * non-specific low back pain * must be pain at least 3 months exclusion criteria: * history of any lumbar spine surgery * presence of neurological deficit * having been diagnosed with cardiovascular or systemic diseases that would prevent him / her from taking exercise training. * the presence of persistent severe pain * pain below the knee * severe/progressive scoliosis * spinal stenosis * spondylolisthesis * cancer * diabetes * metabolic syndrome * inflammatory, infectious or tumoral disease of the vertebra

Keywords: low back pain exercise cognitive aerobic yoga
clinical evaluation of hydrogel and silicone hydrogel daily disposable toric contact lenses

Conditions: Astigmatism

Summary: this study was to evaluate the patient subjective experiences of two daily disposable toric contact lenses.

this was a participant masked, interventional, prospective, direct refit, bilateral wear study. the purpose of this study was to evaluate the patient subjective experiences of a hydrogel daily disposable toric contact lens when compared to a silicone hydrogel daily disposable toric contact lens after 15 minutes of daily wear each.

Eligibility criteria:
inclusion criteria: a person was eligible for inclusion in the study if he/she: * is at least 18 years of age and has full legal capacity to volunteer. * has read and signed an information consent letter. * self-reports having a full eye examination in the previous two years. * anticipates being able to wear the study lenses for at least 8 hours a day, 5 days a week. * is willing and able to follow instructions and maintain the appointment schedule. * habitual soft contact lens wearers who currently wear toric contact lenses, or use spectacles for all distances vision correction, for the past 3 months minimum. * has a contact lens spherical prescription between plano to - 10.00 (inclusive) best corrected visual acuity of 20/30 or better in either eye. * has refractive astigmatism no less than -0.75d and no more than 1.75d in both eyes. * can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logmar) or better in each eye. * can achieve a distance visual acuity of 20/30 (0.18 logmar) or better in each eye with the study contact lenses. * has clear corneas and no active ocular disease. * has read, understood, and signed the information consent letter. exclusion criteria: a person was excluded from the study if he/she: 1. is participating in any concurrent clinical or research study. 2. has any known active ocular disease and/or infection that contraindicates contact lens wear. 3. has a systemic condition that in the opinion of the investigator may affect a study outcome variable. 4. is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable. 5. has known sensitivity to the diagnostic sodium fluorescein used in the study. 6. self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment. 7. has undergone refractive error surgery or intraocular surgery.
a tripartite biopsychosocial intervention program enhances mental health and quality of life in elderly patients with depression secondary to geriatric diseases

Conditions: Depression Anxiety Disorder; Geriatric Diseases; Mental Health and Quality of Life in Elderly Patients

Summary: the biopsychosocial integrated intervention program is an effective model for improving holistic health in elderly patients with geriatric disease-related secondary depression, significantly alleviating depressive symptoms, enhancing mental health, and elevating quality of life.

to investigate the effects of a tripartite biopsychosocial intervention program on mental health and quality of life in elderly patients with depression secondary to geriatric diseases. a cluster randomized controlled trial was conducted with 166 elderly patients with secondary depression in our hospital between january 2022 and january 2025. wards were randomized into an intervention group (n = 83) and a control group (n = 83) using spss-generated random sequences. the intervention group received a biopsychosocial integrated program, while the control group received standard psychiatric care. outcomes were assessed at baseline, 1, 2, and 3 months post-intervention using the 17-item hamilton rating scale for depression (hamd-17), mental health indicators \[profile of mood states (poms), five facet mindfulness questionnaire (ffmq), and mental health continuum-short form (mhc-sf)\], and the generic quality of life inventory-74 (gqoli-74). patient satisfaction was evaluated post-intervention.

Eligibility criteria:
inclusion criteria: diagnosis of depression secondary to geriatric disease (icd-10 criteria) age ≥60 years baseline hamd-17 score ≥14 (mild depression or worse) mini-mental state examination (mmse) score ≥24 (no significant cognitive impairment) willing and able to provide informed consent (patient or guardian) stable on current medications for ≥4 weeks prior to enrollment exclusion criteria: primary psychiatric disorders: schizophrenia or bipolar disorder severe personality disorders active suicidal ideation or psychotic symptoms recent treatment history: antipsychotic medication within 3 months electroconvulsive therapy within 6 months participation in other interventional trials neurological conditions: alzheimer's disease or vascular dementia parkinson's disease with cognitive impairment brain tumors or traumatic brain injury medical comorbidities: terminal illness with life expectancy \<6 months uncontrolled cardiovascular disease severe hepatic/renal insufficiency (gfr \<30 ml/min) substance abuse disorders (alcohol or drugs within past year)
retinal imaging study of children that might be at risk of having retinal hemorrhages

Conditions: Retinal Hemorrhage, Bilateral; Retinal Hemorrhage, Left Eye; Retinal Hemorrhage, Right Eye

Summary: this is a clinical trial in which we will learn about the retinal findings in three clinical groups of children, who might be at risk of having retinal hemorrhages (rh). the aim of the study is to explore the occurrence of moderate to severe retinal hemorrhages in critically ill children, children with intracranial hemorrhages, hydrocephalus or signs of elevated intracranial pressure and in children with benign enlargement of subarachnoid spaces (bess). 1. are rhs associated with bess? 2. what is the prevalence, distribution and extent of rhs in critically ill children? 3. what is the prevalence, distribution and extent of rhs in children with traumatic brain injury? 4. does the prevalence, distribution and extent of rhs differ in children with witnessed traumatic brain injury from children with traumatic brain injury of unknown origin? 5. to what extent do the causes of rhs affect visual acuity, initially and during recovery? a retinal ophthalmoscopy through dilated pupils will be conducted and a fundus photograph will be taken by a handheld, non-touch camera.

the prospective study will take place at university hospitals in three swedish regions, stockholm, skåne and västra götaland. the data collection from the three regions will proceed in parallel over a three-year period. an estimated number of children will be 400-500 per year. the study children will be consecutively referred to the pediatric ophthalmology units, where the ophthalmological examinations will take place. bedside examinations will be performed when indicated at the pediatric intensive care units. retinal fundus examination will be performed according to clinical standards following administration of pupil dilating eye drops in each eye. visual function will be evaluated if ophthalmic abnormalities are detected. prospective observational study group 1: all infants ≤ 18 months of age, who undergo neuroradiological examinations of the brain on the indication increased head circumference. group 2: all critically ill children \< 15 years of age, cared for at the hospitals, with neurological symptoms, that require neuroradiological examination of the brain. group 3: all children ≤ 2 years of age, who undergo emergency neuroradiological examinations of the head at the hospitals.

Eligibility criteria:
inclusion criteria: * infants ≤ 18 months of age, who undergo neuroradiological examinations of the brain on the indication increased head circumference * children \< 15 years of age, cared for at the icu, with neurological symptoms, that require neuroradiological examination of the brain * children \< 5 years of age, who undergo emergency neuroradiological examinations of the head at the hospitals exclusion criteria - infants with intraventricular hemorrhages due to prematurity, in the absence of increased head circumference

Keywords: retinal hemorrhage
a pharmacokinetic (pk) study evaluating naproxen and esomeprazole plasma levels

Conditions: Arthritis

Summary: a pharmacokinetic study evaluating naproxen and esomeprazole blood levels in 4 treatments, each containing one or both components.

this study is being conducted to assess the relative bioavailability of naproxen and esomeprazole from a single dose of pn 400 (delayed-release naproxen 500mg / immediate-release esomeprazole 20mg), enteric-coated naproxen 500mg co-administered with enteric-coated esomeprazole 20mg, enteric-coated naproxen 500mg administered alone, and enteric-coated esomeprazole 20mg administered alone.

Eligibility criteria:
inclusion criteria: * healthy males and non-pregnant, non-lactating females who are either of non-childbearing potential or using an acceptable method of birth control. exclusion criteria: * standard exclusion criteria for a study of this nature - no significant medical conditions that might affect the interpretation of the pk data or compromise the safety of the subject.
bilateral superficial cervical block for thyroidectomy

Conditions: Cervical Pain

Summary: the objective of this study is to compare the postoperative analgesia afforded by bilateral superficial cervical block using different concentrations of local anesthetic (ropivacaine) in patients undergoing total thyroidectomy for the mini-incision technique, performed by the same surgical team.

in this study we will evaluate the efficacy of bilateral superficial cervical block associated with balanced general anesthesia with remifentanil as opioid of choice in preventing postoperative pain in patients who underwent total thyroidectomy with mini incision without neck dissection.a hundred and twenty patients asa i - ii will be assessed and allocated randomly (through a table of random numbers) into three groups for analgesia for post-operative: group 1: bilateral superficial cervical block with 20 ml of 0.9% saline (placebo); group 2: bilateral superficial cervical block with 20 ml ropivacaine 0.25%; group 3: bilateral superficial cervical block with 20 ml ropivacaine 0.5%.

Eligibility criteria:
inclusion criteria: * age greater than 18 years * agreed to participate in the study and sign the consent form * asa i-ii * scheduled to undergo total thyroidectomy without neck dissection under general balanced anesthesia. exclusion criteria: * clinical history or laboratory tests suggestive of bleeding disorder * mental or cognitive deficit in existence, which makes it impossible to understand the patient visual analog scale of pain or the study protocol * body mass index greater than 45 * history of allergy to local anesthetics * intolerance or contraindication to any medication used in the study * skin infection at the site of the blockade * patients requiring neck dissection * pregnancy * preoperative use of opioid analgesics or non-opioids, corticosteroids or anti inflammatory non steroidal * patient's refusal to participate in the study * need for emergency reintervention within the first 24 hours postoperatively

Keywords: superficial cervical block thyroidectomy pain
disclosure intervention for people in treatment for opioid use disorder

Conditions: Opioid Use Disorder

Summary: the goal of this clinical trial is to test a disclosure intervention among people in treatment for opioid use disorder. the main question it aims to answer is whether people who receive a disclosure intervention have better treatment- and recovery-related outcomes one year after receiving the intervention. participants will complete a brief disclosure intervention designed to help them (1) make key disclosures related to disclosure and (2) build skills to disclose. researchers will compare results to participants in a waitlist comparator condition, who receive the intervention at the end of the study.


Eligibility criteria:
inclusion criteria: * client of brandywine counseling \& community services * receiving opioid use disorder treatment at brandywine counseling \& community services * considering disclosing one's opioid use disorder history and/or treatment to someone new exclusion criteria: * diagnosis of schizophrenia * participation in pilot study of intervention

Keywords: disclosure social isolation stigma social support
phase i clinical study of mbs301 in treatment of her2 positive recurrent or metastatic malignant solid tumor

Conditions: HER2-positive Recurrent or Metastatic Malignant Solid Tumor

Summary: this is a phase i study evaluating the safety and pharmacokinetics of mbs301 after intravenous administration in patients with her-2 positive recurrent or metastatic malignant solid tumors


Eligibility criteria:
inclusion criteria: 1. patients with her2-positive recurrent or metastatic malignant solid tumor diagnosed by histopathology or cytology. 2. patients with any types of malignant solid tumors who have progressed despite standard therapy or are intolerant of standard therapy, or for which no standard therapy exists. 3. patients should have measurable lesions or immeasurable lesions (according to recist 1.1). 4. ecog physical condition: 0 or 1 point. 5. expected survival period exceeds 12 weeks. exclusion criteria: 1. absolute neutrophils count (anc) is less than1.5×109/l and/or blood platelets less than 100 ×109/l and/or hemoglobin less than 9g/dl. 2. total bilirubin is more than 1.5 ×uln. 3. patients without hepatic metastasis, alt or ast is more than 1.5 ×uln; patients with hepatic metastasis, alt or ast is more than 3 ×uln. 4. serum creatinine is more than 1.5 × uln or estimated creatinine clearance \<50 ml/min(according to cockcroft-gault). 5. international normalized ratio (inr) is more than 1.5 × uln or activated partial thromboplastin time (aptt) is more than 1.5 × uln. 6. patient has prior treated with anthracyclineswhich accumulated dose is equivalent to adriamycin≥360mg/m2. 7. patient has been experienced toxic reactions after previous anticancer therapy and has not recovered to grade 0 or grade 1 (except for hair loss). 8. known a history with brain metastasis. 9. have a history of liver disease of clinical significance. 10. known to be human immunodeficiency virus (hiv) positive.

Keywords: her2-positive solid tumor mbs301
comparison of arixtra vs. lovenox to prevent blood clots in medically ill patients

Conditions: Venous Thrombosis

Summary: a total of 50 patients \>40 yrs of age with an expected hospital stay in the medical intensive care or regional heart unit at lvh muhlenberg of 6 days or longer will be enrolled. the patient and study team will be blinded to which drug they are receiving (either arixtra or lovenox). subjects will be examined for any bleeding complications. subjects will receive drug for a total of 6-14 days while in the hospital. a follow up phone call will be performed by the study team approximately 30 days after discharge from the hospital.

a total of 50 patients will be enrolled in this double-blinded, randomized, controlled trial. inclusion criteria: subjects\>40 yrs of age with an expected hospital stay in the medical intensive care or regional heart unit at lvh muhlenberg of 6 days or longer (4 days bedridden) will be enrolled. total drug treatment will be 6-14 days while in the hospital. a follow up phone call will be performed by the study team approximately 30 days after hospital discharge. primary endpoint: bleeding rate (minor vs major) between study days 1-14. secondary endpoint: dvt study days 1-14 (confirmed with le duplex ultrasonogram).

Eligibility criteria:
inclusion criteria: * male or female \> 40 years of age. * pt with expected stay in hospital 6 days or \>, with expectation to be bedridden for \> 4 days. * pts admitted to the micu, regional heart units of lv-mhc exclusion criteria: * surgical primary admission diagnosis * recent surgery within the past 12 weeks * planned surgery on the current admission * pregnancy * vent-dependent respiratory failure requiring intubation for \>24 hours. * known current dvt or pe prior to enrollment in study. * creatinine clearance \< 30 ml/min (calculated by the cockcroft-gault method) in a well-hydrated patient. * hx of prior or current lower upper or lower gi bleed. * platelet count \< 100,000 per cubic millimeter * current or prior anticoagulation within the prior 48 hours, excluding a single dose \&lor 24 hour period of prophylactic agent * bacterial endocarditis. * hemophilia * hypersensitivity to aspirin. * hypersensitivity to arixtra or lovenox * hx of hemorrhagic or ischemic stroke \< 3 months prior to enrolling * hematocrit \< 28%. * sbp \>200 mmhg or dbp \>120 mmhg * positive for occult blood in stool. * admission to hospital for \> 48 hours prior to randomization * documented congenital or acquired bleeding disorder * indwelling intrathecal or epidural catheter * life expectancy \< 30 days * inability to have a flu assessment post-discharge from the hospital

Keywords: bleeding rates prophylaxis for deep vein thrombosis
19f hot spot mri of human adipose-derived stem cells for breast reconstruction

Conditions: Breast Cancer

Summary: six female patients (\>18 years of age, pre-menopausal) who have had loco-regional (lumpectomy and radiation) therapy for breast carcinoma and have been at least one-year disease free will undergo liposuction, the autologous svf cell fraction will be isolated and labeled with cs-1000 in the operating room without entering cell culture, which will then be returned to the patient at the site of breast grafting. patients will receive a pre-screening mri . patients will have an mri scans over a period of 1 month at johns hopkins. follow-up mris at 6,12, and 18 months will also be performed. only at johns hopkins with fluorine being done as part of this investigational study. by performing fluorine mri and quantification of 19f signal, we hypothesize that the engraftment of transplanted cells can be tracked in ways not possible before, using the total fluorine signal as surrogate marker for cell persistence and survival. we expect that a clinically successful outcome (maintenance of breast contour and volume) will be positively correlated with cell survival. the outcome of this study may pave the way for using 19f mri cell tracking as a new tool for stem cell therapy in a variety of clinical applications.


Eligibility criteria:
inclusion criteria: 1. patient capable and willing to sign the informed consent (see attached document) 2. patient must be willing to complete all visits in this study 3. female, \>18 years of age 4. lumpectomy and radiation therapy for breast carcinoma 5. 18 month disease free survival 6. no evidence of metastatic disease 7. patient is fit for surgery as determined by preoperative medical clearance workup performed by an independent primary care physician. 8. negative pregnancy test. exclusion criteria: 1. evidence of metastatic disease 2. less than 18 months disease-free interval 3. unable to undergo mri: 3a) metallic implant 3b) claustrophobic 4) high risk for surgical intervention because of comorbidities 5) received treatment with an investigational drug within 30 days of screening.

Keywords: 19f mri